Opko Health Inc. (NYSE:OPK) Given Average Recommendation of “Buy” by Brokerages
Opko Health Inc. (NYSE:OPK) has earned a consensus rating of “Buy” from the ten research firms that are presently covering the stock. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $14.27.
Several research analysts recently commented on the stock. Jefferies Group reaffirmed a “hold” rating on shares of Opko Health in a research note on Wednesday, August 17th. Oppenheimer Holdings Inc. reaffirmed a “market perform” rating on shares of Opko Health in a research note on Thursday, August 11th. JPMorgan Chase & Co. set a $14.00 target price on shares of Opko Health and gave the stock a “buy” rating in a research note on Tuesday, August 9th. Zacks Investment Research raised shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Finally, Standpoint Research lifted their target price on shares of Opko Health from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, June 21st.
In other Opko Health news, CEO Phillip Md Et Al Frost bought 15,800 shares of the company’s stock in a transaction dated Wednesday, July 13th. The shares were purchased at an average price of $9.65 per share, for a total transaction of $152,470.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $29,615,377.15. The purchase was disclosed in a filing with the SEC, which is available at this link.
Several hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its stake in shares of Opko Health by 6.1% in the second quarter. California State Teachers Retirement System now owns 682,157 shares of the company’s stock worth $6,371,000 after buying an additional 39,160 shares during the period. Teachers Advisors Inc. boosted its stake in shares of Opko Health by 3.6% in the first quarter. Teachers Advisors Inc. now owns 325,172 shares of the company’s stock worth $3,379,000 after buying an additional 11,403 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Opko Health by 3.7% in the second quarter. Bank of New York Mellon Corp now owns 1,343,344 shares of the company’s stock worth $12,547,000 after buying an additional 47,942 shares during the period. BlackRock Group LTD boosted its stake in shares of Opko Health by 19.1% in the first quarter. BlackRock Group LTD now owns 251,817 shares of the company’s stock worth $2,616,000 after buying an additional 40,321 shares during the period. Finally, Jaffetilchin Investment Partners LLC boosted its stake in shares of Opko Health by 1.2% in the second quarter. Jaffetilchin Investment Partners LLC now owns 450,450 shares of the company’s stock worth $4,207,000 after buying an additional 5,182 shares during the period.
Opko Health (NYSE:OPK) opened at 10.69 on Thursday. The company’s 50 day moving average is $10.01 and its 200-day moving average is $10.12. The firm has a market cap of $5.88 billion and a P/E ratio of 44.73. Opko Health has a 52-week low of $7.12 and a 52-week high of $11.85.
Opko Health (NYSE:OPK) last posted its quarterly earnings results on Monday, August 8th. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.05. The business had revenue of $357.10 million for the quarter, compared to analysts’ expectations of $324.11 million. The company’s revenue was up 742.2% compared to the same quarter last year. During the same period last year, the business posted ($0.09) earnings per share. On average, equities analysts predict that Opko Health will post ($0.05) EPS for the current fiscal year.
About Opko Health
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.